AVRO -57% cumulatively—(Monday/Tuesday)—on updated phase-1 data for AVR-RD-01 in Fabry disease: https://finance.yahoo.com/news/avrobio-announces-updated-clinical-data-110000571.html http://www.evaluate.com/vantage/articles/news/snippets/avrobio-offers-gene-therapy-bulls-lesson-investing Even after this precipitous drop, AVRO is still +17% from its IPO price in Jun 2018 (#msg-141690245).